The appropriate osha standard for hazard communication

Under the HCS, employers must establish a training and information program for all employees routinely exposed to hazardous chemicals in their workplace.

From: Management of Medical Technology, 1992

REGULATIONS

Carlos M. Nunez, ... Fritz Schweinsberg, in Handbook of Solvents (Third Edition), 2019

18.1.6.1.3 Hazard Communication Standard

The Hazard Communication Standard (HCS) was established to provide workers the “right-to-know” of potential hazards associated with their jobs. HCS is a proactive measure to disseminate information to workers and employers about the health hazards pertaining to the chemicals they handle and the protection required. Employers are required to prepare and implement a hazard communication (HAZCOM) program, ensure that all containers have appropriate labels, provide employees easy access to MSDSs, and conduct training programs. The HAZCOM program is the written plan of action that describes the standard implementation strategy for a given facility.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9781927885413500085

CODES, STANDARDS, AND REGULATIONS

In Management of Medical Technology, 1992

4 Employee Training

Under the HCS, employers must establish a training and information program for all employees routinely exposed to hazardous chemicals in their workplace. This training must be provided at the time of initial assignment and whenever a new hazard is introduced. The standard is performance-oriented, specifying the results but not mandating the methods to be used. At a minimum, the following topics must be thoroughly covered:

The Health Communication Standard: Employees must be informed of the existence of the HCS, what it requires, and what it will do for them.

Terminology: Must be understandable.

MSDSs: Availability and content.

Labels.

The written HCS program.

Specific chemicals used by each employee.

Appropriate personal protective equipment.

First aid and emergency procedures.

It is advisable to document which employees have been trained and when they received the training. If any Subpart Z substances with specific health standards are used, their specific requirements for safe use must be incorporated into the training program.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780750692526500126

SOLVENTS USE IN VARIOUS INDUSTRIES

GEORGE WYPYCH, ... GEORGE WYPYCH, in Handbook of Solvents (Third Edition), 2019

13.9.2.1.2 Hazard Communication Standard (HCS) (29 CFR 1910.1200)

The HCS requires information on hazardous chemicals to be transmitted to employees through labels, material safety data sheets (MSDS), and training programs. A written hazard communications program and record keeping are also required.

A substance is a “hazardous chemical” if it is a “physical hazard” or a “health hazard”. A flammable or explosive liquid is a “physical hazard”. A flammable liquid means “any liquid having a flash point below 110°F (37.8°C), except any mixture having components with flash points of 100°F (37.8°C) or higher, the total of which make up 99% or more of the total volume of the mixture”. “Health hazard” means “a chemical for which there is statistically significant evidence based on at least one valid study that acute or chronic health effects may occur in exposed employees”. Hexane and all the solvents listed in Table 13.9.3 would require MSDS since all are flammable liquids (physical hazards) as defined by OSHA and/or possible health hazards because all, except hexane isomers, have a U.S. OSHA PEL. However, hexane isomers have an American Conference of Industrial Hygienist (ACGIH) threshold limit value (TLV),10 which many states and countries enforce as a mandatory standard.

Chemical manufacturers and importers are required to review the available scientific evidence concerning the hazards of chemicals they produce or import, and to report the information to manufacturing employers who use their products. If a chemical mixture has not been tested as a whole to determine whether the mixture is a hazardous chemical, the mixture is assumed to present the same hazards as do the components that comprise 1% or greater of the mixture or a carcinogenic hazard if it contains a component in concentration of 0.1% or greater that is a carcinogen. Commercial hexane containing 52% n-hexane has been tested and found not to be neurotoxic, unlike pure n-hexane.11–13 So mixtures with less than 52% n-hexane should not be considered to be a neurotoxin, although n-hexane would have to be listed on the MSDS, if in greater quantity than 1% of the mixture.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9781927885413500036

Occupational Toxicology Testing☆

E.V. Sargent, ... C.S. Schwartz, in Reference Module in Biomedical Sciences, 2017

OSHA Hazard Communication Standard

The Occupational Safety and Health Administration (OSHA) Hazard Communication Standard (HCS) (United States Department of Labor, Occupational Safety and Health Administration, 2012) is representative of one type of performance-oriented standard among occupational safety and health regulations. The standard requires chemical manufacturers to evaluate the hazards of chemicals they produce or import. Based on the hazard evaluation, the standard requires that labels and SDSs be prepared according to specified criteria to convey hazard information and protective measures to employees and downstream users. The HCS is considered a performance-oriented regulation because it covers all hazardous chemicals and types of employment but, other than specifying classification of hazards, selection of hazard phrases, and labeling content, does not stipulate how to comply with its requirements. HCS does not require testing of materials, but rather relies on available data. Under the “General Duty” clause of the Occupational Safety and Health Act of 1970, the manufacturers are clearly responsible for maintaining a safe workplace and consequently using all available data for evaluating the hazards of materials produced. The health hazards, as classified, that accompany OSHA Hazard Communications Standard are listed in Table 2. (Note: Specification of physical hazards, also included in the HCS, is considered beyond the scope of this discussion; the reader is referred to the text of HCS for further detail.)

Table 2. Toxicological hazard classification schemes according to the Globally Harmonized System (GHS) of Classification and Labeling of Chemicals (2013), the US OSHA HCS (2012; “HazCom 2012”), the EU Regulation on classification, packaging and labelling (2008; “EU CPL”), the EU Directive on Classification and Labeling (1967), and the Canadian WHMIS (1988)

GHSOSHA HazCom 2012EU CPLEU DirectiveWHMIS
Acute toxicity
Category 1Category 1 Category 1 Very toxic Class D, Division 1, Subdivision A, Very Toxic
Oral LD50 ≤ 5 mg kg− 1Oral LD50 ≤ 5 mg kg− 1 Oral LD50 ≤ 5 mg kg− 1 Oral LD50 ≤ 25 mg kg− 1 (R28) Oral LD50 ≤ 50 mg kg− 1
Dermal LD50 ≤ 50 mg kg− 1Dermal LD50 ≤ 50 mg kg− 1 Dermal LD50 ≤ 50 mg kg− 1 Dermal LD50 ≤ 50 mg kg− 1 (R27) Dermal LD50 ≤ 200 mg kg− 1
Inhalation, gas: 4 h LC50 ≤ 100 ppmInhalation, gas: 4 h LC50 ≤ 100 ppm Inhalation, gas: 4 h LC50 ≤ 100 ppm Inhalation LC50 ≤ 500 mg kg− 3 (4 h) (R26) Gases LC50 ≤ 2,500 ppm (4 h)
Inhalation, vapors: 4 h LC50 ≤ 0.5 mg L− 1Inhalation, vapors: 4 h LC50 ≤ 0.5 mg L− 1 Inhalation, vapors: 4 h LC50 ≤ 0.5 mg L− 1 Serious nonlethal acute effects at similar doses (R39) (Symbol includes T +) Vapors LC50 ≤ 1,500 ppm (4 h)
Inhalation, dust/mist: 4 h LC50 ≤ 0.05 mg L− 1Inhalation, dust/mist: 4 h LC50 ≤ 0.05 mg L− 1 Inhalation, dust/mist: 4 h LC50 ≤ 0.05 mg L− 1 Dust, mist, fume (1 h) LC50 ≤ 500 mg m− 3
Category 2Category 2 Category 2
Oral LD50 > 5 mg kg− 1, ≤ 50 mg kg− 1Oral LD50 > 5 mg kg− 1, ≤ 50 mg kg− 1 Oral LD50 > 5 mg kg− 1, ≤ 50 mg kg− 1 (See Criteria for “Very Toxic,” above) (See Criteria for “Class D, Division 1, Subdivision A, Very Toxic,” above)
Dermal LD50 > 50 mg kg− 1, ≤ 200 mg kg− 1Dermal LD50 > 50 mg kg− 1, ≤ 200 mg kg− 1 Dermal LD50 > 50 mg kg− 1, ≤ 200 mg kg− 1
Inhalation, gas: 4 h LC50 > 100 ppm, ≤ 500 ppmInhalation, gas: 4 h LC50 > 100 ppm, ≤ 500 ppm Inhalation, gas: 4 h LC50 > 100 ppm, ≤ 500 ppm
Inhalation, vapors: 4 h LC50 > 0.5 mg L− 1, ≤ 2.0 mg L− 1Inhalation, vapors: 4 h LC50 > 0.5 mg L− 1, ≤ 2.0 mg L− 1 Inhalation, vapors: 4 h LC50 > 0.5 mg L− 1, ≤ 2.0 mg L− 1
Inhalation, dust/mist: 4 h LC50 > 0.05 mg L− 1, ≤ 0.5 mg L− 1Inhalation, dust/mist: 4 h LC50 > 0.05 mg L− 1, ≤ 0.5 mg L− 1 Inhalation, dust/mist: 4 h LC50 > 0.05 mg L− 1, ≤ 0.5 mg L− 1
Category 3Category 3 Category 3 Toxic Class D, Division 1, Subdivision B, Toxic
Oral LD50 > 50 mg kg− 1, ≤ 300 mg kg− 1Oral LD50 > 50 mg kg− 1, ≤ 300 mg kg− 1 Oral LD50 > 50 mg kg− 1, ≤ 300 mg kg− 1 25 mg kg− 1 < oral LD50 ≤ 200 mg kg− 1 (R25) Oral LD50 > 50 mg kg− 1, ≤ 500 mg kg− 1
Dermal LD50 > 200 mg kg− 1, ≤ 1,000 mg kg− 1Dermal LD50 > 200 mg kg− 1, ≤ 1,000 mg kg− 1 Dermal LD50 > 200 mg kg− 1, ≤ 1,000 mg kg− 1 50 mg kg− 1 < dermal LD50 ≤ 400 mg kg− 1 (R24) Dermal LD50 > 200 mg kg− 1, ≤ 1,000 mg kg− 1
Inhalation, gas: 4 h LC50 > 500 ppm, ≤ 2,500 ppmInhalation, gas: 4 h LC50 > 500 ppm, ≤ 2,500 ppm Inhalation, gas: 4 h LC50 > 500 ppm, ≤ 2,500 ppm Inhalation (4 h) ≥ 500 mg m− 3 < LD50 ≤ 400 mg m− 3 Inhalation vapor (4 h) LC50 > 1,500 ppm, ≤ 2,500 ppm
Inhalation, vapors: 4 h LC50 > 2.0 mg L− 1, ≤ 10 mg L− 1Inhalation, vapors: 4 h LC50 > 2.0 mg L− 1, ≤ 10 mg L− 1 Inhalation, vapors: 4 h LC50 > 2.0 mg L− 1, ≤ 10 mg L− 1 Similar nonlethal acute effects at similar doses (R39) (Symbol includes T) Inhalation dust, mist, fume (4 h) LC50 > 500 mg m− 3, ≤ 2,500 mg m− 3
Inhalation, dust/mist: 4 h LC50 > 0.5 mg L− 1, ≤ 1.0 mg L− 1Inhalation, dust/mist: 4 h LC50 > 0.5 mg L− 1, ≤ 1.0 mg L− 1 Inhalation, dust/mist: 4 h LC50 > 0.5 mg L− 1, ≤ 1.0 mg L− 1
Category 4Category 4 Category 4 Harmful
Oral LD50 > 300 mg kg− 1, ≤ 2,000 mg kg− 1Oral LD50 > 300 mg kg− 1, ≤ 2,000 mg kg− 1 Oral LD50 > 300 mg kg− 1, ≤ 2,000 mg kg− 1 200 mg kg− 1 < oral LD50 ≤ 2,000 mg kg− 1 (R22)
Dermal LD50 > 1,000 mg kg− 1, ≤ 2,000 mg kg− 1Dermal LD50 > 1,000 mg kg− 1, ≤ 2,000 mg kg− 1 Dermal LD50 > 1,000 mg kg− 1, ≤ 2,000 mg kg− 1 400 mg kg− 1 < dermal LD50 ≤ 2,000 mg kg− 1 (R21)
Inhalation, gas: 4 h LC50 > 2,500 ppm, ≤ 20,000 ppmInhalation, gas: 4 h LC50 > 2,500 ppm, ≤ 20,000 ppm Inhalation, gas: 4 h LC50 > 2,500 ppm, ≤ 20,000 ppm Inhalation (4 h) 2,000 mg kg− 3 < LD50 ≤ 20,000 mg kg− 3 (R20)
Inhalation, vapors: 4 h LC50 > 10 mg L− 1, ≤ 20 mg L− 1Inhalation, vapors: 4 h LC50 > 10 mg L− 1, ≤ 20 mg L− 1 Inhalation, vapors: 4 h LC50 > 10 mg L− 1, ≤ 20 mg L− 1 Serious, nonlethal, acute effects at similar doses (R40) (Symbol includes Xn)
Inhalation, dust/mist: 4 h LC50 > 1.0 mg L− 1, ≤ 5.0 mg L− 1Inhalation, dust/mist: 4 h LC50 > 1.0 mg L− 1, ≤ 5.0 mg L− 1 Inhalation, dust/mist: 4 h LC50 > 1.0 mg L− 1, ≤ 5.0 mg L− 1
Category 5Not adopted by US OSHA Not adopted by EU
Oral LD50 > 2,000 mg kg− 1, ≤ 5,000 mg kg− 1
Dermal LD50 > 2,000 mg kg− 1, ≤ 5,000 mg kg− 1
Inhalation, gas: 4 h LC50 > 20,000 ppm
Inhalation, vapors: 4 h LC50 > 20 mg L− 1
Inhalation, dust/mist: 4 h LC50 > 5.0 mg L− 1
Skin corrosion/irritation
Corrosive (may be subdivided to Category 1A, 1B, or 1C, dependent on time for lesion to occur)Corrosive Corrosive Causes severe burns (R35) Class E
Irreversible damage to the skin, that is, visible necrosis through the epidermis to the dermis following application for up to 4 hIrreversible damage to the skin, that is, visible necrosis through the epidermis to the dermis following application for up to 4 h
Subdivided to Category 1A, 1B, or 1C, dependent on time for lesion to occur.Irreversible damage to the skin, that is, visible necrosis through the epidermis to the dermis following application for up to 4 h
Subdivided to Category 1A, 1B, or 1C, dependent on time for lesion to occur.Full thickness destruction of skin tissue occurs with up to 3 min exposure Corrosive to skin in accordance with OECD 404; or
Positive evidence of visible necrosis of human tissue
Corrosive SAE 1020 steel or 7075-T6 nonclad aluminum at > 6.25 mm year− 1 at 55°C; or
In Class 8, Part III, TDG; or
Gas in Division 4, Class 2, Part III, TDG.
Causes burns (R35)
Full thickness destruction of skin tissue occurs with up to 4 h exposure. (No mention of corrosivity to metals.) (Symbol C)
Category 2: IrritantCategory 2: Irritant Category 2: Irritant Skin irritation (R38) Class D, Division 2, Subdivision B, Toxic (Skin)
Mean value of ≥ 2.3, ≤ 4.0 for erythema/eschar or edema in at least two of three animals from gradings at 24, 48, and 72 h after patches removed or inflammation that persists for 14 days in at least two animals or where there is pronounced variability, very positive effects in one animalMean value of ≥ 2.3, ≤ 4.0 for erythema/eschar or edema in at least two of three animals from gradings at 24, 48, and 72 h after patches removed or inflammation that persists for 14 days in at least two animals or where there is pronounced variability, very positive effects in one animal Mean value of ≥ 2.3, ≤ 4.0 for erythema/eschar or edema in at least two of three animals from gradings at 24, 48, and 72 h after patches removed or inflammation that persists for 14 days in at least two animals or where there is pronounced variability, very positive effects in one animal Erythema formation, OECD 404 grade ≥ 2; edema formation, OECD 404 grade 2. Significant inflammation is caused and remains present for more than 24 h Erythema formation OECD 404 grade ≥ 2, edema formation, OECD 404 grade ≥ 2
Category 3: Mild irritant
≥ 1.5, ≤ 2.3 for erythema/eschar or edema in at least two of three animals from gradings at 24, 48, and 72 h after patches removed or (if reactions are delayed) from grades on 3 consecutive days after the onset of skin reactions)Not adopted by US OSHA Not adopted by EU
Serious eye damage/eye irritation
Category 1: Serious eye damage/irreversible effects on the eyeCategory 1: Serious eye damage/irreversible effects on the eye Category 1: serious eye damage/irreversible effects on the eye Serious damage to eyes (R41) Class D, Division 2, Subdivision B, Toxic (Eyes)
Irreversible effects (21 days) on the cornea, iris, or conjunctiva in at least one animal or effects in two of three animals: cornea ≥ 3 and/or iris ≥ 1.5 as mean score over 24, 48, and 72 hIrreversible effects (21 days) on the cornea, iris, or conjunctiva in at least one animal or effects in two of three animals: cornea ≥ 3 and/or iris ≥ 1.5 as mean score over 24, 48, and 72 h Irreversible effects (21 days) on the cornea, iris, or conjunctiva in at least one animal or effects in two of three animals: cornea ≥ 3 and/or iris ≥ 1.5 as mean score over 24, 48, and 72 h Severe corneal damage, grade ≥ 3*; Iris lesions, grade ≥ 1.5*
*per OECD 405Corneal damage, grade ≥ 2*; iris damage, grade ≥ 1*; conjunctival swelling and/or redness, grade ≥ 2.5*
*per OECD 405
Category 2(2A): IrritantCategory 2(2A): Irritant Category 2: Irritant Eye irritation (R36)
Effects in two of three animals: cornea ≥ 1 and/or iris ≥ 1, and/or conjunctival redness or swelling ≥ 2, as mean score over 24, 48, and 72 h. Effects fully reversible within 21 daysEffects in two of three animals: cornea ≥ 1 and/or iris ≥ 1, and/or conjunctival redness or swelling ≥ 2, as mean score over 24, 48, and 72 h. Effects fully reversible within 21 days Effects in two of three animals: cornea ≥ 1 and/or iris ≥ 1, and/or conjunctival redness or swelling ≥ 2, as mean score over 24, 48, and 72 h. Effects fully reversible within 21 days Corneal damage, grade ≥ 2, but < 3*; iris damage, grade ≥ 1, but < 1.5*; conjunctival edema ≥ 2*; conjunctival redness ≥ 2.5*
Significant ocular lesions are caused and remain present for more than 24 h
*per OECD 405
Category 2B: Mild irritant (reversible)Category 2B: Mild irritant (reversible) Not adopted by EU
Effects in two of three animals: cornea ≥ 1 and/or iris ≥ 1, and/or conjunctival redness or swelling ≥ 2, as mean score over 24, 48, and 72 h. Effects fully reversible within 7 daysEffects in two of three animals: cornea ≥ 1 and/or iris ≥ 1, and/or conjunctival redness or swelling ≥ 2, as mean score over 24, 48, and 72 h. Effects fully reversible within 7 days
Skin sensitization
Category 1: Skin sensitizerCategory 1: Skin sensitizer Category 1: Skin sensitizer Irritant (R43) Class D, Division 2, Subdivision B, Toxic
Evidence in humans that the substance can lead to sensitization by skin contact in a substantial number of persons; or positive results from an appropriate animal test. Divided into Categories 1A (Anticipated high frequency or potency in animals) and 1B (Anticipated low to moderate frequency or probability)Evidence in humans that the substance can lead to sensitization by skin contact in a substantial number of persons; or positive results from an appropriate animal test. Divided into Categories 1A (Anticipated high frequency or potency in animals) and 1B (Anticipated low to moderate frequency or probability) Evidence in humans that the substance can lead to sensitization by skin contact in a substantial number of persons; or positive results from an appropriate animal test. (Note: no subdivision to Categories 1A and 1B) If sensitization reaction is noted in a significant human or animal population following exposure OECD 406 produces response in ≥ 30% of test animals with use of an adjuvant; or produces response with ≥ 15% of test animals without the use of an adjuvant; or positive evidence of workplace skin sensitization.
Respiratory tract sensitization
Category 1: Respiratory sensitizerCategory 1: Respiratory sensitizer Category 1: Respiratory sensitizer Harmful Class D, Division 2, Subdivision A, Very Toxic
Evidence in humans that the substance can lead to specific respiratory hypersensitivity and/or positive results from an appropriate animal test. Divided into Categories 1A (Anticipated high frequency or probability of occurrence) and 1B (Anticipated low to moderate frequency or probability)Evidence in humans that the substance can lead to specific respiratory hypersensitivity and/or positive results from an appropriate animal test. Divided into Categories 1A (Anticipated high frequency or probability of occurrence) and 1B (Anticipated low to moderate frequency or probability) Evidence in humans that the substance can lead to specific respiratory hypersensitivity and/or positive results from an appropriate animal test. (Note: no subdivision to Categories 1A and 1B) Capable of inducing a sensitization reaction in humans by inhalation at a greater than expected frequency than in normal population. (R24) (Symbol includes Xn) Evidence of respiratory tract sensitization following workplace exposure
Mutagenicity
Category 1: Germ cell mutagenCategory 1: Germ cell mutagen Category 1: Germ cell mutagen Mutagenic
Known (1A) or presumed (1B) germ cell mutagen.
Category 1A is based on positive epidemiologic evidence in humans.
Category 1B is based on positive results from mammalian in vivo heritable germ cell mutagenicity data, or in vivo somatic cell mutagenicity tests with supporting evidence that the substance has potential to cause germ cell mutations; or positive evidence of germ cell mutations in humansKnown (1A) or presumed (1B) germ cell mutagen.
Category 1A is based on positive epidemiologic evidence in humans.
Category 1B is based on positive results from mammalian in vivo heritable germ cell mutagenicity data, or in vivo somatic cell mutagenicity tests with supporting evidence that the substance has potential to cause germ cell mutations; or positive evidence of germ cell mutations in humansKnown (1A) or presumed (1B) germ cell mutagen.
Category 1A is based on positive epidemiologic evidence in humans.
Category 1B is based on positive results from mammalian in vivo heritable germ cell mutagenicity data, or in vivo somatic cell mutagenicity tests with supporting evidence that the substance has potential to cause germ cell mutations; or positive evidence of germ cell mutations in humansCategory 1: known to be mutagenic to man Category 2: regarded as mutagenic to man Falls into Subdivision A, Very Toxic, if: there is epidemiological evidence of heritable genetic effects; or there is evidence of mutagenicity in mammalian germ cells in vivo, in accordance with specified test methods.
Category 2: Germ cell mutagenCategory 2: Germ cell mutagen Category 2: Germ cell mutagen
Chemicals that cause concern that they may induce heritable germ cell mutations based on somatic cell mutagenicity tests in vivo in mammals or other somatic cell in vivo tests supported by positive results from other in vitro mutagenicity assaysChemicals that cause concern that they may induce heritable germ cell mutations based on somatic cell mutagenicity tests in vivo in mammals or other somatic cell in vivo tests supported by positive results from other in vitro mutagenicity assays Chemicals that cause concern that they may induce heritable germ cell mutations based on somatic cell mutagenicity tests in vivo in mammals or other somatic cell in vivo tests supported by positive results from other in vitro mutagenicity assays Category 3: Causes concern owing to possible mutagenic effects Falls into Subdivision B, Toxic, if: there is evidence of mutagenicity in mammalian somatic cells obtained in vivo in specified tests assessing gene mutation or chromosomal aberration
Carcinogenicity
Category 1: CarcinogenCategory 1: Carcinogen Category 1: Carcinogen Carcinogenic Subdivision A, Very Toxic
Known or presumed human carcinogens
The classification of a substance as a Category 1 carcinogen is done on the basis of epidemiological and/or animal data. This classification is further subdivided:
Category 1A: Known to have carcinogenic potential for humans. Classification in this category is largely based on human evidence.
Category 1B: Presumed to have carcinogenic potential for humans. Classification in this category is largely based on animal evidence.Known or presumed human carcinogens
The classification of a substance as a Category 1 carcinogen is done on the basis of epidemiological and/or animal data. This classification is further subdivided:
Category 1A: Known to have carcinogenic potential for humans. Classification in this category is largely based on human evidence.
Category 1B: Presumed to have carcinogenic potential for humans. Classification in this category is largely based on animal evidence.Known or presumed human carcinogens
The classification of a substance as a Category 1 carcinogen is done on the basis of epidemiological and/or animal data. This classification is further subdivided:
Category 1A: Known to have carcinogenic potential for humans. Classification in this category is largely based on human evidence.
Category 1B: Presumed to have carcinogenic potential for humans. Classification in this category is largely based on animal evidence.Group A: Known human carcinogen
Group B: Probable human carcinogenListed in Section A 1A, A 1B, or A2 of Appendix A of the Threshold Limit Values for Chemical Substances and Physical Agencies in the Work Environment, published by the ACGIH; or listed in Group 1 or Group 2 in the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, published by The World Health Organization
Category 2: CarcinogenCategory 2: Carcinogen Category 2: Carcinogen
Suspected human carcinogens
The classification of a substance in Category 2 is done on the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place the substance in Category 1A or 1B.Suspected human carcinogens
The classification of a substance in Category 2 is done on the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place the substance in Category 1A or 1B.Suspected human carcinogens
The classification of a substance in Category 2 is done on the basis of evidence obtained from human and/or animal studies, but which is not sufficiently convincing to place the substance in Category 1A or 1B.Group C: Possible human carcinogen
Reproductive toxicity
Category 1: Reproductive toxicantCategory 1: Reproductive toxicant Category 1: Reproductive toxicant Toxic to reproduction Subdivision A, Very Toxic:
Known (1A) or Presumed (1B) human reproductive toxicant, based primarily on human or animal evidence, respectively. (Differentiated into effects on fertility and development)Known (1A) or Presumed (1B) human reproductive toxicant, based primarily on human or animal evidence, respectively. (Differentiated into effects on fertility and development) Known (1A) or Presumed (1B) human reproductive toxicant, based primarily on human or animal evidence, respectively. (Differentiated into effects on fertility and development) Category 1: Known to impair fertility or cause developmental toxicity (teratogenicity) to man (Toxic); Category 2: Regarded as if they impair fertility or cause developmental toxicity (teratogenicity) to man (Toxic) Shown to cause death, malformation, permanent metabolic or physiological dysfunction, growth retardation, psychological or behavioral alteration during pregnancy, at birth, or in postnatal period.
Category 2: Reproductive toxicantCategory 2: Reproductive toxicant Category 2: Reproductive toxicant
Suspected human reproductive toxicant, based primarily on animal evidence not sufficiently convincing to place it in Category 1Suspected human reproductive toxicant, based primarily on animal evidence not sufficiently convincing to place it in Category 1 Suspected human reproductive toxicant, based primarily on animal evidence not sufficiently convincing to place it in Category 1 Category 3: Suspected of causing concern for human fertility or for causing cause developmental toxicity (teratogenicity) to man (Harmful)
Effects on lactationEffects on lactation Effects on lactation May cause harm to breastfed babies
Substances that are absorbed by women and have been shown to interfere with lactation or that may be present (including metabolites) in breast milk in amounts sufficient to cause concern for the health of a breastfed childChemicals that are absorbed by women and have been shown to interfere with lactation or that may be present (including metabolites) in breast milk in amounts sufficient to cause concern for the health of a breastfed child Substances that are absorbed by women and have been shown to interfere with lactation or that may be present (including metabolites) in breast milk in amounts sufficient to cause concern for the health of a breastfed child Substances and preparations that are absorbed by women and may interfere with lactation or that may be present (including metabolites) in breast milk in amounts sufficient to cause concern for the health of a breastfed child
Specific target organ toxicity—single exposure
STOT—SE, Category 1STOT—SE, Category 1 STOT—SE, Category 1
Substances that have produced significant toxicity (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following single exposure.
NOAEL Classification Guidance:
Oral dose ≤ 300 mg kg− 1;
Dermal dose ≤ 1,000 mg kg− 1;
Inhalation concentration (gas) ≤ 2,500 ppm/4 h;
Inhalation concentration (vapor) ≤ 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) ≤ 1.0 mg L− 1/4 h.Substances that have produced significant toxicity (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following single exposure.
NOAEL Classification Guidance:
Oral dose ≤ 300 mg kg− 1;
Dermal dose ≤ 1,000 mg kg− 1;
Inhalation concentration (gas) ≤ 2,500 ppm/4 h;
Inhalation concentration (vapor) ≤ 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) ≤ 1.0 mg L− 1/4 h.Substances that have produced significant toxicity (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following single exposure.
NOAEL Classification Guidance:
Oral dose ≤ 300 mg kg− 1;
Dermal dose ≤ 1,000 mg kg− 1;
Inhalation concentration (gas) ≤ 2,500 ppm/4 h;
Inhalation concentration (vapor) ≤ 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) ≤ 1.0 mg L− 1/4 h.
STOT—SE, Category 2STOT—SE, Category 2 STOT—SE, Category 2
Substances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful (causing functional disturbance or morphological change) to human health following single exposure.
NOAEL Classification Guidance:
Oral dose 2,000 ≥ C > 300 mg kg− 1;
Dermal dose 2,000 ≥ C > 1,000 mg kg− 1;
Inhalation concentration (gas) 20,000 ≥ C > 2,500 ppm/4 h;
Inhalation concentration (vapor) 20 ≥ C > 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) 5.0 ≥ C > 1.0 mg L− 1/4 h.Substances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful (causing functional disturbance or morphological change) to human health following single exposure.
NOAEL Classification Guidance:
Oral dose 2,000 ≥ C > 300 mg kg− 1;
Dermal dose 2,000 ≥ C > 1,000 mg kg− 1;
Inhalation concentration (gas) 20,000 ≥ C > 2,500 ppm/4 h;
Inhalation concentration (vapor) 20 ≥ C > 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) 5.0 ≥ C > 1.0 mg L− 1/4 h.Substances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful (causing functional disturbance or morphological change) to human health following single exposure.
NOAEL Classification Guidance:
Oral dose 2,000 ≥ C > 300 mg kg− 1;
Dermal dose 2,000 ≥ C > 1,000 mg kg− 1;
Inhalation concentration (gas) 20,000 ≥ C > 2,500 ppm/4 h;
Inhalation concentration (vapor) 20 ≥ C > 10 mg L− 1/4 h;
Inhalation concentration (dust/mist/fume) 5.0 ≥ C > 1.0 mg L− 1/4 h.
STOT—SE, Category 3STOT—SE, Category 3 STOT—SE, Category 3
Substances that cause transient target organ effects such as narcosis and respiratory tract irritation.
NOAEL Classification Guidance do not applySubstances that cause transient target organ effects such as narcosis and respiratory tract irritation.
NOAEL Classification Guidance do not applySubstances that cause transient target organ effects such as narcosis and respiratory tract irritation.
NOAEL Classification Guidance do not apply
Specific target organ toxicity—repeated exposure
STOT—RE, Category 1STOT—RE, Category 1 STOT—RE, Category 1 Toxic Class D, Division 2, Subdivision B, Toxic
Substances that have produced significant toxicity harmful (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following repeated or prolonged exposure.
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose ≤ 10 mg kg− 1/day;
Dermal dose ≤ 20 mg kg− 1/day;
Inhalation concentration (gas) ≤ 50 ppm/6 h/day;
Inhalation concentration (vapor) ≤ 0.2 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) ≤ 0.02 mg L− 1/6 h/daySubstances that have produced significant toxicity harmful (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following repeated or prolonged exposure.
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose ≤ 10 mg kg− 1/day;
Dermal dose ≤ 20 mg kg− 1/day;
Inhalation concentration (gas) ≤ 50 ppm/6 h/day;
Inhalation concentration (vapor) ≤ 0.2 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) ≤ 0.02 mg L− 1/6 h/daySubstances that have produced significant toxicity harmful (causing functional disturbance or morphological change) in humans, or that, on the basis of evidence from studies in experimental animals can be presumed to have the potential to produce significant toxicity in humans following repeated or prolonged exposure.
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose ≤ 10 mg kg− 1/day;
Dermal dose ≤ 20 mg kg− 1/day;
Inhalation concentration (gas) ≤ 50 ppm/6 h/day;
Inhalation concentration (vapor) ≤ 0.2 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) ≤ 0.02 mg L− 1/6 h/dayDanger of functional disturbance or morphological change by repeated or prolonged exposure at:
Oral dose < 5 mg kg− 1/day (R22);
Dermal dose < 10 mg kg− 1/day (R21)
Inhalation concentration < 50 mg m− 3 (R20)
(Apply directly to 90 days subchronic; guidelines to interpret subacute (28 days) or chronic (2 years) studies)Effects of sufficient severity to threaten life or cause serious, permanent impairment in ≥ 90-day test at:
Oral: 10 mg kg− 1 day < oral dose ≤ 100 mg kg− 1/day;
Dermal: 20 mg kg− 1/day < dermal dose ≤ 200 mg kg− 1/day;
Gases and vapor: 25 ppm < inhalation concentration ≤ 100 mg kg− 3;
Dust, mist, fume: 10 mg kg− 3 < inhalation concentration ≤ 100 mg m− 3.
STOT—RE, Category 2STOT—RE, Category 2 STOT—RE, Category 2 Harmful
Substances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful to human health following repeated or prolonged exposure.
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose 10 ≥ C > 100 mg kg− 1/day;
Dermal dose 20 ≥ C > 200 mg kg− 1/day;
Inhalation concentration (gas) 50 ≥ C > 250 ppm/6 h/day;
Inhalation concentration (vapor) 0.2 ≥ C > 1.0 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) 0.02 ≥ C > 0.2 mg L− 1/6 h/daySubstances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful to human health following repeated or prolonged exposure
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose 10 ≥ C > 100 mg kg− 1/day;
Dermal dose 20 ≥ C > 200 mg kg− 1/day;
Inhalation concentration (gas) 50 ≥ C > 250 ppm/6 h/day;
Inhalation concentration (vapor) 0.2 ≥ C > 1.0 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) 0.02 ≥ C > 0.2 mg L− 1/6 h/daySubstances that, on the basis of evidence from studies in experimental animals, can be presumed to have the potential to be harmful to human health following repeated or prolonged exposure
NOAEL Classification Guidance (based on 90-day study; extrapolate doses to 28-day or chronic studies):
Oral dose 10 ≥ C > 100 mg kg− 1/day;
Dermal dose 20 ≥ C > 200 mg kg− 1/day;
Inhalation concentration (gas) 50 ≥ C > 250 ppm/6 h/day;
Inhalation concentration (vapor) 0.2 ≥ C > 1.0 mg L− 1/6 h/day;
Inhalation concentration (dust/mist/fume) 0.02 ≥ C > 0.2 mg L− 1/6 h/day.Danger of functional disturbance or morphological change by repeated or prolonged exposure at:
Oral dose < 50 mg kg− 1/day (R22);
Dermal dose < 100 mg kg− 1/day (R21)
Inhalation concentration < 500 mg m− 3 (R20)
(Apply directly to 90 days subchronic; guidelines to interpret subacute (28 days) or chronic (2 years) studies.)
Aspiration Hazard
Category 1Category 1 Category 1 Harmful: May cause lung damage if swallowed Not classified
Reliable and good quality human evidence indicate that the chemical causes aspiration toxicity; or
It is a hydrocarbon and has a kinematic viscosity of ≤ 20.5 mm2 s− 1 (@40°C).Reliable and good quality human evidence indicates that the chemical causes aspiration toxicity; or
It is a hydrocarbon and has a kinematic viscosity of ≤ 20.5 mm2 s− 1 (@40°C).Reliable and good quality human evidence indicates that the chemical causes aspiration toxicity; or
It is a hydrocarbon and has a kinematic viscosity of ≤ 20.5 mm2 s− 1 (@40°C).Liquid substances and preparations presenting an aspiration hazard in humans because of their low viscosity, as measured by specified testing; or
Based on practical experience in humans.
Category 2
Evidence from animal studies and expert judgment, based on key physical properties, other than those substances that are in Category 1, that have a kinematic viscosity of ≤ 14 mm2 s− 1 (@40°C).Not adopted by US OSHA Not adopted by EU
Biohazardous infectious material
Not classifiedNot classified Not classified Not classified Class D, division 3
An organism and its toxins that has been shown, or is believed, to cause disease in persons or animals

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780128012383019450

OSHA Requirements for Lead Construction

In Construction Hazardous Materials Compliance Guide: Lead Detection, Abatement, and Inspection Procedures, 2012

Employee information and training

The employer shall communicate information concerning lead hazards according to the requirements of OSHA's Hazard Communication Standard for the construction industry, 29 CFR 1926.59, including but not limited to the requirements concerning warning signs and labels, material safety data sheets (MSDS), and employee information and training. In addition, employers shall comply with the following requirements:

The employer shall train each employee who is subject to exposure to lead at or above the action level on any day, or who is subject to exposure to lead compounds which may cause skin or eye irritation (e.g., lead arsenate, lead azide), in accordance with the requirements of this section. The employer shall institute a training program and ensure employee participation in the program.

The employer shall provide the training program as initial training prior to the time of job assignment or prior to the start-up date for this requirement, whichever comes last.

The employer shall also provide the training program at least annually for each employee who is subject to lead exposure at or above the action level on any day.

The employer shall ensure that each employee is trained in the following:

The content of this standard and its appendices

The specific nature of the operations that could result in exposure to lead above the action level

The purpose, proper selection, fitting, use, and limitations of respirators

The purpose and a description of the medical surveillance program, and the medical removal protection program including information concerning the adverse health effects associated with excessive exposure to lead (with particular attention to the adverse reproductive effects on both males and females and hazards to the fetus and additional precautions for employees who are pregnant)

The engineering controls and work practices associated with the employee's job assignment including training of employees to follow relevant good work practices

The contents of any compliance plan in effect; instructions to employees that chelating agents should not routinely be used to remove lead from their bodies and should not be used at all except under the direction of a licensed physician; and the employee's right of access to records under 29 CFR 1910.20

Access to Information and Training Materials

At a minimum, the employee should have access to information and training materials, as follows:

The employer shall make readily available to all affected employees a copy of this standard and its appendices.

The employer shall provide, on request, all materials relating to the employee information and training program to affected employees and their designated representatives, and to the Assistant Secretary and the Director.

The employer may use signs required by other statutes, regulations, or ordinances in addition to, or in combination with, signs required by this paragraph.

The employer shall ensure that no statement appears on or near any sign required by this paragraph that contradicts or detracts from the meaning of the required sign.

The employer shall post a warning sign, such as the following, in each work area where employees may have exposure to lead that is above the PEL.

The employer shall ensure that signs required by this paragraph are illuminated and cleaned as necessary so that the legend is readily visible.

WARNING

LEAD WORK AREA

POISON

NO SMOKING OR EATING

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780124158382000040

Managing Nanotechnology Risks in Small Business—A National Institute for Occupational Safety and Health Perspective

Laura L. Hodson, Charles L. Geraci, in Nanotechnology Environmental Health and Safety (Third Edition), 2018

11.10 Product Stewardship

Product stewardship means taking responsibility for the environmental, safety, and health impact of products at key points during the life cycle of the material, including design, manufacture, use, recycling, and disposal. This stewardship is especially important when developing a new material because the initiative and the costs of dealing with such matters will fall on the developer. Customers, workers, disposal services, and other end users of the material may each have different requirements when it comes to accepting the material.

The health communication standard (HCS) requires chemical manufacturers, distributors, or importers to provide SDSs to communicate the hazards of hazardous chemical products. As of June 1, 2015, the HCS requires new SDSs to be in a uniform format with 16 specified sections (OSHA, 2012) including

1.

Identification

2.

Hazard(s) identification

3.

Composition/information on ingredients

4.

First-aid measures

5.

Fire-fighting measures

6.

Accidental release measures

7.

Handling and storage

8.

Exposure controls/personal protection

9.

Physical and chemical properties

10.

Stability and reactivity

11.

Toxicological information

12.

Ecological information (nonmandatory)

13.

Disposal considerations (nonmandatory)

14.

Transport information (nonmandatory)

15.

Regulatory information (nonmandatory)

16.

Other information, including date of preparation or last revision

The International Standards Organization (ISO)/TR 13329:2012 standard, Nanomaterials—Preparation of Material SDS, also provides guidance on the development of content for, and consistency in, the communication of information on safety, health, and environmental matters in SDS for substances classified as manufactured nanomaterials and for chemical products containing manufactured nanomaterials.

Additional and equal important product stewardship activities should include product safety testing, proper labeling, noting any possible transportation issues (e.g., dangerous goods), responding to customer inquiries, compliance with product safety regulations, consideration, and guidance for recycling and disposal.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780128135884000117

General Mold Remediation Methods

R. Dodge Woodson, in Construction Hazardous Materials Compliance Guide: Mold Detection, Abatement and Inspection Procedures, 2012

NYC DOH recommends training building maintenance staff who will conduct remediation work on the potential health hazards of mold. This training can be conducted as part of the training needed to comply with the OSHA Hazard Communication Standard (29 CFR 1910.1200). Health Canada suggests that building maintenance personnel and maintenance staff be aware of potential problems associated with contaminated indoor air, and USEPA indicates that remediation workers, and particularly those with health-related concerns, might wish to consult with a health-care provider before working on mold remediation or investigating potentially moldy areas. Both USEPA and New York City's DOH recommend communication with building occupants throughout the remediation process. When mold contamination requiring a large-scale response is found, building occupants should be notified of that fact and given a description and timetable of the activities that will take place. The form (e.g., memos, meetings) and extent of communication will depend on the degree of contamination and nature of the remediation work.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780124158405000051

Chemicals

Ian SuttonAuthor, in Plant Design and Operations (Second Edition), 2017

OSHA Requirements

For companies operating in the United States, the design, content, and application of an MSDS are explained in detail in Occupational Safety and Health Administration (OSHA)’s 1910.1200 (g) Hazard Communication Standard (HCS). Some of the key points with regard to this four-page standard are as follows:

The manufacturer and/or distributor of a chemical is responsible for writing and distributing the MSDS.

The MSDS must contain information describing the hazardous properties of the chemical.

Flammability and explosive properties of the chemical.

First aid and other treatment measures should be described.

A name and address of where more information can be obtained, if needed.

OSHA provides the following guidance with respect to MSDS:

Chemical manufacturers and importers are required to obtain or develop a material safety data sheet for each hazardous chemical they produce or import. Distributors are responsible for ensuring that their customers are provided a copy of these MSDSs. Employers must have an MSDS for each hazardous chemical which they use. Employers may rely on the information received from their suppliers. The specific requirements for material safety data sheets are in paragraph (g) of the standard…

The role of MSDSs under the rule is to provide detailed information on each hazardous chemical, including its potential hazardous effects, its physical and chemical characteristics, and recommendations for appropriate protective measures. This information should be useful to you as the employer responsible for designing protective programs, as well as to the workers. If you are not familiar with material safety data sheets and with chemical terminology, you may need to learn to use them yourself. A glossary of MSDS terms may be helpful in this regard. Generally speaking, most employers using hazardous chemicals will primarily be concerned with MSDS information regarding hazardous effects and recommended protective measures. Focus on the sections of the MSDS that are applicable to your situation.

MSDSs must be readily accessible to employees when they are in their work areas during their workshifts. This may be accomplished in many different ways. You must decide what is appropriate for your particular workplace. Some employers keep the MSDSs in a binder in a central location (e.g., in the pick-up truck on a construction site). Others, particularly in workplaces with large numbers of chemicals, computerize the information and provide access through terminals. As long as employees can get the information when they need it, any approach may be used. The employees must have access to the MSDSs themselves—simply having a system where the information can be read to them over the phone is only permitted under the mobile worksite provision, paragraph (g)(9), when employees must travel between workplaces during the shift. In this situation, they have access to the MSDSs prior to leaving the primary worksite, and when they return, so the telephone system is simply an emergency arrangement.

When conducting an inspection, OSHA looks for the following information to do with MSDS:

Designation of person(s) responsible for obtaining and maintaining the MSDSs.

How the sheets are to be accessed and kept up to date in the workplace.

Procedures to follow when the MSDS is not received at the time of the first shipment.

For producers, procedures to update the MSDS when new and significant health information is found.

Description of alternatives to actual data sheets in the workplace, if used.

For employers using hazardous chemicals, the most important aspect of the written program in terms of MSDSs is to ensure that someone is responsible for obtaining and maintaining the MSDSs for every hazardous chemical in the workplace. The list of hazardous chemicals required to be maintained as part of the written program will serve as an inventory. As new chemicals are purchased, the list should be updated. Many companies have found it convenient to include on their purchase orders the name and address of the person designated in their company to receive MSDS.

Within the United States there is no regulation as to how often MSDSs should be updated or revalidated. Canadian law requires that this be done at least every 3 years; this update frequency is often used as a good practice, even when it is not a legal requirement.

OSHA states the following regarding storing MSDS in electronic format only:

If the employee’s work area includes the area where the MSDSs can be obtained, then maintaining MSDSs on a computer would be in compliance. If the MSDSs can only be accessed out of the employee’s work area(s), then the employer would not be in compliance with 1910.1200(g)(8) or (9) and 1926.59 (h)(1)(i-v).

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780128128831000176

OSHA Workplace Guidelines for Mold

R. Dodge Woodson, in Construction Hazardous Materials Compliance Guide: Mold Detection, Abatement and Inspection Procedures, 2012

Level I: Small Isolated Areas

The following applies to 10 sq. ft or less areas; for example, ceiling tiles and small areas on walls.

Remediation can be conducted by the regular building maintenance staff as long as they are trained on proper cleanup methods, personal protection, and potential health hazards. This training can be performed as part of a program to comply with the requirements of the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Respiratory protection (e.g., N95 disposable respirator) is recommended. Respirators must be used in accordance with the OSHA respiratory protection standard (29 CFR 1910.134). Gloves and eye protection should be worn.

The work area should be unoccupied. Removing people from spaces adjacent to the work area is not necessary, but is recommended for infants (<12 months old), persons recovering from recent surgery, immune-suppressed people, or people with chronic inflammatory lung diseases (e.g., asthma, hypersensitivity pneumonitis, and severe allergies).

Containment of the work area is not necessary. Dust suppression methods, such as misting (not soaking) surfaces prior to remediation, are recommended.

Contaminated materials that cannot be cleaned should be removed from the building in a sealed impermeable plastic bag. These materials may be disposed of as ordinary waste.

The work area and areas used by remediation workers for egress should be cleaned with a damp cloth or mop and a detergent solution.

All areas should be left dry and visibly free from contamination and debris.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780124158405000038

Recognition, Evaluation and Control of Some Plasma Processing Hazards

David Rainer, Lisa Brooks, in Semiconductor Safety Handbook, 1998

7.0 SOURCES OF INFORMATION

There are many sources of toxicology data relevant to plasma etching processes. Hopefully, the occupational health and safety program of the employer or educational institution will have adequately prepared each worker to read, understand, and follow the information on material safety data sheets (MSDSs) and labels. The authors are equally hopeful that each manufacturer/supplier of hazardous chemicals has exercised due diligence in preparing the MSDSs, labels, and other product information. It is recognized, however, that the OSHA Hazard Communication Standard (29 CFR 1910.1200) mandates collection and presentation of data on hazardous substances and does not require that information be generated. This distinction means that there is not necessarily any incentive to conduct, for example, toxicology studies to identify potential health hazards, industrial hygiene tests to refine monitoring methods and to define appropriate materials for personal protective equipment, or biomedical research to identify useful biomedical tests and treatment therapies.

The toxicology, industrial hygiene, occupational medicine, and safety professionals responsible for a workplace will be invaluable resources for health and safety information. These professionals often draw on a wealth of experience relevant to the plasma etching processes and are in the best possible position to apply “academic” information to actual workplace situations. They have often partnered with commercial vendors and suppliers to improve recognition and control of hazards and to make such findings available to the research community through journal articles, training materials, personal interactions, and textbooks such as this one. Recent responsible care and regulatory incentives have led several chemical manufacturers to develop and institute product stewardship programs which further facilitate information sharing as well as health, safety, and environmental protection.

The secondary reference materials on which the authors have relied in the compilation of this toxicology information are listed below; primary references can be found in and identified from those secondary references. In addition, the reader is referred to the on-line databases available through the National Library of Medicine (NLM) of the U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.[25] The dozens of biomedical and toxicology databases available through NLM contain information from thousands of major publications, including peer-reviewed technical journals and regulatory agency documents. The NLM databases usually reflect the most recent available information and they often serve as the only convenient source for information submitted for regulatory compliance. The databases are fully searchable and can be accessed with user-friendly software.

Read full chapter

URL: https://www.sciencedirect.com/science/article/pii/B9780815514183500138

What is Hazard Communication Standard?

The OSHA Hazard Communication Standard is designed to ensure chemical safety in the workplace. The standard, which requires workplaces to provide written information about the identities and hazards associated with the chemicals, must be available and understandable to workers.

What is the purpose of the OSHA Hazard Communication Standard?

Purpose. The purpose of this section is to ensure that the hazards of all chemicals produced or imported are classified, and that information concerning the classified hazards is transmitted to employers and employees.

What are the six major parts of OSHA Hazard Communication Standard?

The Standard contains six major categories: Hazard Classification, Written Hazard Communication Program, Labels and other Forms of Warning, Safety Data Sheets, Employee Information and Training and Trade Secrets.

How many hazard communication standards are there?

The Hazard Communication standard requires all the hazardous information of a chemical used in the workplace, which covers physical, health, and environmental impacts, to be effectively communicated to those working with it. There are five key factors of the Hazard Communication Standard.